The International Contrast Ultrasound Society (ICUS)

GE Healthcare Files Supplemental New Drug Application for Its Own Manufacturing of Optison

Upon Approval, GE Healthcare's Oslo Facility Will Provide Stock to the US Becoming Only Contrast Media Manufacturer to Supply Its Own Stock to the US Market

PRINCETON, NJ, January 15, 2013 – GE Healthcare today announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture OptisonTM (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility. Optison is a contrast agent that may improve the visualization of the left ventricular border – an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. Upon approval, GE Healthcare will provide supply of Optison to the US market from its manufacturing facility in Oslo, becoming the only contrast media manufacturer to supply its own stock for the US.

For the full article, please click on the attached document.

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:

dentons-logo2

silver-level

Toshiba Medical logo resized

samsung-logo

siemens-new-original

philips-icus-logo

mindray

ICUS Tweets

Follow Bubble Conference 2016 comment at #bubble2016
Connect live now to the 31st Annual Advances in Contrast Ultrasound "Bubble Conference" taking place in Chicago; https://t.co/67SmoW2GLn
FDA approves new liver imaging agent for adults and children; reduces exposure to harmful radiation. More at: https://t.co/3qa1vDFFhW

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS News GE Healthcare Files Supplemental New Drug Application for Its Own Manufacturing of Optison